The medication, formerly known as KarXT, is the first antipsychotic medication to target cholinergic receptors rather than dopamine receptors, according to a Sept. 26 news release from the agency.
Cobenfy’s effectiveness was demonstrated in two clinical studies, each lasting five weeks and involving randomized, double-blind, placebo-controlled settings. The studies assessed the drug’s ability to reduce symptoms as measured by the Positive and Negative Syndrome Scale, showing significant improvements in participants compared to the placebo group, the release said.
Schizophrenia affects 1% of Americans, according to the FDA.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
